AR and prostate cancer: When combined with Enzalutamide, an androgen receptor inhibitor, SR48692 also reduced neuroendocrine differentiation and slowed tumor growth in prostate cancer xenografts, suggesting that targeting the NT system could delay castration-resistant prostate cancer progression [70].